Literature DB >> 18846102

Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection.

Norberto Perico1, Ariela Benigni, Giuseppe Remuzzi.   

Abstract

At present, there are no specific cures for most of the acquired chronic kidney diseases, and renal transplantation is limited by organ shortage, therefore present efforts are concentrated on the prevention of progression of renal diseases. There is robust experimental and clinical evidence that progression of chronic nephropathies is multifactorial; however, intraglomerular haemodynamic changes and proteinuria play a key role in this process. With a focus on renoprotection, we first examine more established therapies--such as those that modulate the renin-angiotensin-aldosterone system--that can be used for the treatment of proteinuric renal diseases. We then discuss examples of novel drugs and biologics that might be used to target the inflammatory and profibrotic process, and glomerular injury, highlighting results from recent clinical trials.

Entities:  

Mesh:

Year:  2008        PMID: 18846102     DOI: 10.1038/nrd2685

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  25 in total

1.  Proteinuria: Is the ONTARGET renal substudy actually off target?

Authors:  Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2009-08       Impact factor: 28.314

Review 2.  New short interfering RNA-based therapies for glomerulonephritis.

Authors:  Hideki Shimizu; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2011-05-24       Impact factor: 28.314

3.  Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats.

Authors:  Young Mi Seok; Hae Ahm Lee; Kwon Moo Park; Mi-Hyang Hwangbo; In Kyeom Kim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-22       Impact factor: 3.000

Review 4.  The RAAS in the pathogenesis and treatment of diabetic nephropathy.

Authors:  Piero Ruggenenti; Paolo Cravedi; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

5.  PKC-delta promotes renal tubular cell apoptosis associated with proteinuria.

Authors:  Xiaoning Li; Navjotsingh Pabla; Qingqing Wei; Guie Dong; Robert O Messing; Cong-Yi Wang; Zheng Dong
Journal:  J Am Soc Nephrol       Date:  2010-04-15       Impact factor: 10.121

Review 6.  The next generation of therapeutics for chronic kidney disease.

Authors:  Matthew D Breyer; Katalin Susztak
Journal:  Nat Rev Drug Discov       Date:  2016-05-27       Impact factor: 84.694

7.  Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients.

Authors:  Anna Caroli; Luca Antiga; Sara Conti; Aurelio Sonzogni; Giorgio Fasolini; Patrizia Ondei; Norberto Perico; Giuseppe Remuzzi; Andrea Remuzzi
Journal:  Am J Pathol       Date:  2011-06-17       Impact factor: 4.307

Review 8.  Can we target tubular damage to prevent renal function decline in diabetes?

Authors:  Joseph V Bonventre
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

9.  The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice.

Authors:  Gianluca Grassia; Marcella Maddaluno; Angelo Guglielmotti; Giorgina Mangano; Giuseppe Biondi; Pasquale Maffia; Armando Ialenti
Journal:  Cardiovasc Res       Date:  2009-07-10       Impact factor: 10.787

10.  The role of renin angiotensin system inhibition in kidney repair.

Authors:  Irene M van der Meer; Paolo Cravedi; Giuseppe Remuzzi
Journal:  Fibrogenesis Tissue Repair       Date:  2010-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.